Autotelic Bio develops antisense oligonucleotide (ASO) therapeutics that bind to disease‑specific mRNA transcripts, blocking translation and reducing harmful protein production. Their platform designs custom DNA strands for injectable delivery, enabling precise, rapid development of treatments for genetic, neurodegenerative, and other protein‑mediated disorders. The company targets pharma, biotech, and research organizations seeking nucleic‑acid‑based drug solutions.
Funding
$12.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases are driven by the production of harmful proteins encoded by specific genes, and existing therapies often cannot directly suppress the underlying protein synthesis, leading to limited treatment efficacy.
Solution
AutotelicBio focuses on developing antisense oligonucleotide (ASO) therapeutics that bind to target mRNA sequences, preventing translation of disease-associated proteins at the source. By designing short, synthetic DNA strands that hybridize with specific mRNA transcripts, the platform can selectively down‑regulate pathogenic protein expression. The ASOs are formulated for injection, enabling systemic or localized delivery to affected tissues. This approach aims to provide a molecularly precise treatment option that addresses the root cause of genetic and protein‑driven disorders, improving patient outcomes.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing treatments for genetic, neurodegenerative, and other protein‑mediated diseases, as well as clinical research organizations conducting ASO drug development.
Features
- Custom-designed ASO sequences that target disease‑specific mRNA transcripts
- In‑jection delivery formats optimized for stability and tissue penetration
- Mechanism of action that blocks translation, reducing production of harmful proteins
- Platform capable of rapid iteration from target identification to preclinical candidate
- Compatibility with standard regulatory pathways for nucleic‑acid therapeutics